OC
ALT icon

Oppenheimer & Co’s Altimmune ALT Stock Holding History

Oppenheimer & Co’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-36
Closed -$9K – 1298
2017
Q1 		$9K Hold
36
– – ﹤0.01% 1284
2016
Q4 		$35K Buy
+36
New +$32.3K ﹤0.01% 1254
2013
Q4 		– Sell
-33
Closed -$21K – 1380
2013
Q3 		$21K Buy
+33
New +$18.9K ﹤0.01% 1302

Other funds holding ALT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Oppenheimer & Co's ALT Position: Q2 2017 in Review

Oppenheimer & Co sold out of Altimmune (ALT) in Q2 2017, closing a stake of 36 shares — an estimated $9K sold.

Oppenheimer & Co first reported a position in ALT in Q3 2013 and held it in 3 quarters. The position peaked at $35K in Q4 2016. 41 funds tracked by Wall St. Rank hold ALT as of Q2 2017.

  • Oppenheimer & Co reported no remaining Altimmune position as of Q2 2017 after selling out during the quarter.
  • Oppenheimer & Co sold 36 Altimmune shares in Q2 2017, an estimated $9K.
  • Oppenheimer & Co first reported a position in Altimmune in Q3 2013 and held it in 3 quarters.
  • Oppenheimer & Co's Altimmune position peaked at $35K in Q4 2016.
  • 41 funds tracked by Wall St. Rank held Altimmune as of Q2 2017.

Based on Oppenheimer & Co's 13F filing for Q2 2017, filed 9 Aug 2017.